Navigation Links
Vioxx Ban Tied to Rise in Serious GI Trouble
Date:11/8/2007

Without such stomach-shielding drugs, patient health has suffered, researchers say

THURSDAY, Nov. 8 (HealthDay News) -- Pulling the painkillers Vioxx and Bextra off the market to spare patients' hearts may have ended up harming their stomachs, a new study suggests.

Rates of gastrointestinal events serious enough to require hospitalization have risen significantly since the cox-2 inhibitor medications were ordered off the market in 2004-2005, researchers say.

"It's like our focus shifted from the reason that we were using these drugs -- against GI bleeds -- and onto something else. We left our eye off the ball, and this is what has happened," said study author Dr. Gurkipal Singh, a rheumatologist and a clinical professor of medicine at Stanford University School of Medicine.

His team presented its findings Thursday at the American College of Rheumatology annual meeting, in Boston.

Cox-2 inhibitors such as Vioxx, Bextra and Celebrex are a subset of a larger group of painkillers called non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs such as aspirin, ibuprofen (Advil, Motrin) and naproxen (Aleve) relieve pain, but they also raise risks for GI tract complications, including bleeding.

Cox-2 inhibitors were heralded as a safer alternative to other NSAIDs precisely because they offered users a much lower risk of these side effects.

In their heyday, millions of Americans took the drugs. However, beginning in late 2004, the U.S. Food and Drug Administration called for the withdrawal of Vioxx and then Bextra, after studies suggested higher rates of serious cardiac events in long-time users. Only Celebrex remains on the market.

The Vioxx and Bextra withdrawals may have come at a cost, however, as Americans battling pain reached again for NSAIDs.

In their study, Singh's team tracked the use of cox-2 inhibitors from their introduction in 1999 until the end of 2005. In tot
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. New study may explain Vioxx side-effects
2. Study Points to Cause of Vioxx Heart Risk
3. Longer ambulance journeys boost death risk for seriously ill patients
4. Heartburn Can Be a Sign of Serious Disease
5. Shaking may cause brain damage and serious long-term effects to infants
6. Serious Injury Rare With Police Tasers
7. Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord
8. In the Aftermath: Smoke Odor and Fine Particulate Matter a Serious Concern
9. Quality-of-life yardstick needed for children with serious urologic conditions, Hopkins study shows
10. Hepatitis C treatment reduces the virus but serious liver problems may progress
11. Sleepless Kids Are Troubled Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vioxx Ban Tied to Rise in Serious GI Trouble 
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has announced an ... a new Medicare Advantage Plan for PREFERRED’s provider network ... Arizona counties. The agreement takes effect in two stages: ... and Maricopa and Pima counties will become effective on ... of WellCare of Arizona has Medicare Advantage plans in ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... don’t go to bed or rise early thanks to a ... , Crafty travelers will have a little extra change ... Scottsdale Paradise Valley hotel’s Book Early and Save Up ... advance notice, guests can enjoy the year-round Scottsdale sunshine in ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... researchers at Peterson Medical College, a strategy was developed ... Immunodeficiency Virus (HIV) out of dormancy in the cellular ... Samoan rainforest tree, and appears to stimulate the virus, ... body's immune system to detect and attack it.// ...
... heart attacks more quickly and with greater accuracy if ... ,At the moment, the blood test is usually the ... used earlier on, the researchers argue, it would also ... Baltimore University in Maryland, led the research.// His team ...
... A breakthrough in the treatment of coronary artery disease ... surgery. Medical research has come up with a drug-coated ... has shown an ability to check the recurrence of ... ,The results of this new procedure, based on a ...
... of what causes the fatal autoimmune disease Systemic Lupus ... possible genetic link. ,Researchers at the University of ... possible genetic link to SLE. Their report in a ... in mice which, if absent, causes symptoms remarkably similar ...
... to detect cervical cancer,has been developed by Australians which may ... the UK, Italy, Spain as well as Australia. ,Sydney-based ... with CSIRO and claims that it offers instant results and ... pen-like probe to collect information directly from the cervix about ...
... Scientists working on the 10-year international Human Genome Project ... the highest concentration of disease genes.Out of 23 pairs ... with genetic disease. , Over the next 20 years ... Cambridge, eastern England will have a large impact on ...
Cached Medicine News:Health News:Prostratin- Drug to eradicate HIV 2Health News:Blood test for diagnosis of heart attacks 2Health News:Bypassing open heart bypass surgery... 2Health News:Identification of gene 2
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... 4, 2011 Eli Lilly and Company (NYSE: ... studies of molecules that target genetic mutations and disable ... studies evaluated two unique molecules – a JAK2 inhibitor ... the American Association for Cancer Research (AACR) 102nd Annual ...
... announcing that it entered into an agreement with Oman Pharmaceutical ... Neomycin Sulfate Tablets. Under the terms of the agreement, the ... distributed by Breckenridge on an exclusive basis in the United ... and Drug Administration (FDA), and the companies began shipping the ...
Cached Medicine Technology:Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 2Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 3Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 4
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
The Bair Hugger Model 505 provides safe, quiet and effective warming to patients around the world....
... has it's temperature set by means ... pressing a button. A green LED ... a flashing amber LED indicates the ... A red LED and an audible ...
Medicine Products: